Synergy Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

SGYP 2.99 0.00 (0.00%)
price chart
Synergy Pharmaceuticals, Inc. (SGYP) Surges: Stock Rises 10%
Synergy Pharmaceuticals, Inc. (SGYP - Snapshot Report) was a big mover last session, as the company saw its shares rise 10% on the day.
Related articles »  
Synergy Pharmaceuticals Inc. Announces Pricing of Private Offering of $175 ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the pricing of its private offering of $175 million aggregate principal amount of ...
Related articles »  
Synergy Pharmaceuticals, Inc. (SGYP) Surges: Stock Rises 10% - Tale of the Tape
was a big mover last session, as the company saw its shares rise 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session This continues the recent uptrend for the company as the stock is now up ...
Related articles »  
Synergy Pharma completes patient enrollment plecanatide Phase 3 (SGYP)
All patients have been enrolled in the second of two pivotal Phase 3 studies assessing two doses (3 mg and 6 mg) of Synergy Pharmaceuticals (SGYP +1%) plecanatide in patients with chronic idiopathic constipation (CIC). This follows the completion of ...
Synergy Pharmaceuticals Completes Patient Enrollment for the Second Pivotal ...  Business Wire (press release)
Short Interest of Synergy Pharmaceuticals Inc Drops by 15.9%
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) stated loss of 2,481,555 shares or 15.9% in the short interest. The short interest registered from 15,587,279 on December 15,2014 to 13,105,724 on December 31,2014.
Synergy Pharmaceuticals Inc. Announces Issuance of $200 Million of 7.50 ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the closing of its previously announced private offering of $200 million ...
Related articles »  
Synergy Pharmaceuticals Inc Analyst Rating Update
As many as 2 brokerage firms have rated Synergy Pharmaceuticals Inc (NASDAQ:SGYP) at 1. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of Neutral.
Synergy Pharmaceuticals Inc. Announces Private Offering of Convertible Senior ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) (the �Company�), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that it is offering to sell up to $150 million principal amount of ...
Related articles »  
Synergy Pharmaceuticals Inc (SGYP), Proteon Therapeutics Inc (PRTO): James ...
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and Proteon Therapeutics Inc (NASDAQ:PRTO) are in the spotlight as James E. Flynn's Deerfield Management and Peter Kolchinsky's RA Capital Management started new stakes in them lately.
Cantor Fitzgerald Reaffirms Buy Rating for Synergy Pharmaceuticals (SGYP)  sleekmoney
Related articles »  
Synergy Pharmaceuticals Inc. Announces Full Exercise of Over-Allotment Option
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the full exercise of the over-allotment option granted to the initial purchasers to ...
Related articles »